‘Glaring Gap’ Seen in DNA Privacy Pledges by 23andMe, Ancestry
By Kristen V Brown,
Bloomberg
| 08. 02. 2018
Genetic-testing companies that have decoded the DNA of millions just introduced new guidelines to protect data privacy.
But those best practices failed to address a major concern: what happens to customers’ data that is shared for research with pharmaceutical giants, academics and others, often for a profit.
Just how lucrative the business of genetic testing is came into light last week when British drugmaker GlaxoSmithKline Plc agreed to buy a $300 million stake in 23andMe Inc., gaining access to anonymized data with the hope of identifying new targets for drugs. That kind of data -- stripped of identifying details and aggregated -- isn’t strictly subject to new rules in the guidelines unveiled this week. That means consumers will still have little way to know when and how their information is combed for research.
“This new policy is a positive step forward in the sense that it’s starting a conversation,” said James Hazel, a researcher at Vanderbilt University in Nashville, Tennessee, who recently surveyed the privacy policies of 90 direct-to-consumer genetic-testing companies. “The glaring gap is that it doesn’t apply...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...